| | First author, year, country | Sample size (T/C) | Age, mean ± SD (year) | Sex (M/F) | Treatment group | Control group | Treatment session (week) | Outcome assessment |
| | Teekachunhatean S, 2004, Thailand [19] | 200 (100/100) | T: 62.66 ± 9.46
C: 62.38 ± 8.22 | T: 22/78
C: 19/81 | Duhuo jisheng pills | Diclofenac 25 mg/time, PO, TID | 4 | LES, VS, AE | | Su ZF, 2016, China [26] | 59 (30/29) | T: 58.9
C: 57.1 | T: 8/22
C: 9/20 | Kanggu zengsheng pills | Celecoxib, 200 mg/time, PO, QD | 4 | TER, WS, VS | | Niu QW, 2016, China [27] | 210 (105/105) | T: 59.88 ± 2.41
C: 58.64 ± 2.32 | T: 45/60
C: 44/61 | Jingwu gutong capsule | Diclofenac sodium tablet, 100 mg/time, PO, QD | 4 | KS, VS | | Lv G, 2016, China [28] | 91 (46/45) | T: 54.39 ± 5.24
C: 55.08 ± 4.5 | T: 20/26
C: 21/24 | Qubi tang | Diacerein, 50 mg/time, PO, BID | 12 | TER, AE | | Zhang GL, 2016, China [29] | 88 (44/44) | NA | NA | Cangxi tongbi tang | Etodolac tablet, 400 mg/time, PO, QD | 5 | TER, VS | | Bo Y, 2016, China [30] | 80 (40/40) | T: 51.2
C: 49.8 | T: 19/21
C: 17/23 | Shugan zishen tang | Meloxicam, 7.5 mg/time, PO, QD | 8 | TER, CCR, WS, AE | | Zhang XL, 2016, China [31] | 286 (142/144) | T: 55 ± 7
C: 56 ± 8 | T: 31/105
C: 35/105 | Zhuanggu guanjie pills + placebo | Celecoxib, 200 mg/time, PO, QD + placebo | 4 | TER, CCR, WS, AE | | Li YP, 2015, China [32] | 86 (45/41) | T: 54.5 ± 6.2
C: 53.8 ± 6.3 | T: 19/26
C: 12/29 | Huoxue tongluo bushen fang | Meloxicam, 7.5 mg/time, PO, QD | 4 | TER, AE | | Zhu XY, 2014, China [33] | 70 (35/35) | T: 51.79 ± 7.01
C: 48.62 ± 7.51 | T: 12/21
C: 15/19 | Long bie capsule | Diacerein, 50 mg/time, PO, QD | 4 | AE | | Xu WL, 2014, China [34] | 60 (30/30) | T: 55.6 ± 9.3
C: 52.5 ± 11.4 | T: 11/19
C: 9/21 | Long bie capsule | Celecoxib, 200 mg/time, PO, QD | 4 | WS, AE | | Sun Y, 2014, China [35] | 100 (50/50) | T: 48.25 ± 5.87
C: 49.26 ± 5.15 | T: 15/35
C: 16/34 | Zeng ye run jie tang | Meloxicam, 7.5 mg/time, PO, QD | 8 | TER, CCR, LES, AE | | Zhang JQ, 2014, China [36] | 71 (35/36) | T: 60.45 ± 6.53
C: 62.14 ± 8.14 | T: 9/26
C: 7/29 | Bushen huoxue fang | Celecoxib, 200 mg/time, PO, QD | 12 | TER, CCR, LYS, VS, AE | | Yang HR, 2014, China [37] | 200 (100/100) | T: 65
C: 64 | NA | Jia wei yang he tang | Loxoprofen sodium, 60 mg/time, PO, BID | 8 | KS | | Zhou HJ, 2012, China [38] | 78 (43/35) | T: 53.61 ± 6.37
C: 54.18 ± 6.13 | T: 17/26
C: 14/21 | Shufu Jiangu decoction | Celecoxib, 200 mg/time, PO, QD | 8 | TER, CCR, LYS, VS | | Xu YS, 2013, China [39] | 68 (34/34) | T: 59.17 ± 12.17
C: 62.72 ± 11.64 | NA | Bushen huoxue fang | Celecoxib, 200 mg/time, PO, BID | 6 | WS | | Lu M, 2012, China [40] | 240 (120/120) | T: 52.93 ± 14.22
C: 54.01 ± 15.35 | T: 55/65
C: 50/70 | Tenghuang Jiangu tablet | Celecoxib | 4 | TER, CCR, WS, AE | | Sun SL, 2012, China [41] | 48 (24/24) | T: 62.75
C: 65.75 | NA | Qi teng tang | Meloxicam, 7.5 mg/time, PO, QD | 4 | TER, LES, AE | | Fan XH, 2012, China [42] | 152 (76//76) | T: 50.6 ± 8.2
C: 49.8 ± 7.6 | T: 29/47
C: 35/41 | Jiawei Danggui Sini Tang | Celecoxib, 200 mg/time, PO, QD | 8 | TER, CCR, WS, VS | | Ji MH, 2010, China [43] | 40 (20/20) | T: 50.75 ± 2.12
C: 51.02 ± 1.54 | T: 9/11
C: 9/11 | Buahen huoxue tongluo fang | Celecoxib | 4 | LES, KS | | Yu CG, 2009, China [44] | 200 (100/100) | T: NA; 44/46
C: NA; 52/48 | T: 44/46
C: 52/48 | Bushen huayu tang | Fenbid capsule 200 mg/time, PO, QD | 4 | TER, LES | | Yang B, 2009, China [45] | 60 (30/30) | NA | NA | Bushen huoxue medicinal | Celecoxib, 200 mg/time, PO, QD | 4 | TER, CCR | | Guo YJ, 2010, China [46] | 160 (82/78) | T: 63.93
C: 61.83 | T: 34/48
C: 32/46 | Quyu Tongbi decoction | Diclofenac tablet, 75 mg/time, PO, BID | 2 | TER | | Huang BQ, 2009, China [47] | 60 (32/28) | T: 50.2 ± 87
C: 51.1 ± 10.2 | T: 6/26
C: 11/17 | Bushen zhuanggu fang | Meloxicam, 15 mg/time, PO, QD | 5 | TER, CCR, AE | | Wu JX, 2009, China [48] | 40 (21/19) | T: 56.5
C: 57.3 | T: 4/17
C: 3/16 | Duhuo jisheng decoction | Celecoxib | 4 | LES, KS | | Zhao L, 2008, China [49] | 50 (25/25) | T: 63.09 ± 7.65
C: 62.65 ± 10.8 | T: 2/20
C: 4/19 | Bushen huoxue medicinal | Celecoxib | 4 | VS | | Li M, 2007, China [50] | 120 (60/60) | T: 57.6
C: 55.2 | T: 28/32
C: 27/33 | Gu shu tang | Fenbid capsule, 300 mg/time, PO, BID | 4 | TER, CCR | | Ye JX, 2005, China [51] | 152 (80/72) | T: 59.2 ± 17.6
C: 57.5 ± 15.3 | T: 35/45
C: 31/41 | Guanjietong tablet | Ibuprofen capsule, 300 mg/time, PO, QD | 4 | TER, CCR | | Li YM, 2005, China [52] | 60 (30/30) | T: 58.4
C: 57.2 | NA | Bushen huoxue jianxi fang | Diclofenac tablet, 50 mg/time, PO, BID | 4 | TER, AE | | Wang PM, 2005, China [53] | 40 (20/20) | T: 59.85 ± 10.29
C: 60.1 ± 9.5 | NA | Xining fang | Diclofenac tablet, 75 mg/time, PO, QD | 4 | WS, VS, AE | | Li ZW, 2010, China [54] | 96 (48/48) | T: 52.4 ± 7.6
C: 53.2 ± 8.5 | T: 25/23
C: 22/26 | Bushen huayu tang | Diclofenac sodium tablet, 75 mg/time, PO, BID | 8 | TER, WS | | Wang HD, 2017, China [55] | 48 (24/24) | T: 56.2 ± 8.6
C: 55.7 ± 8.9 | T: 14/10
C: 15/9 | Bushen huoxue tang | Loxoprofen sodium, 60 mg/time, PO, TID | 12 | TER | | Chen N, 2017, China [56] | 90 (45/45) | T: 45.51
C: 45.19 | T: 6/39
C: 6/39 | Bushen qiangjin capsule | Celecoxib, 200 mg/time, PO, QD | 4 | VS, WS, LES, TER, AE | | Zheng T, 2019, China [57] | 100 (50/50) | T: 63.26 ± 4.72
C: 63.12 ± 4.93 | T: 27/23
C: 24/26 | Bushen huoxue fang | Celecoxib, 100 mg/time, PO, BID | 4 | VS, WS, TER, AE | | Li MX, 2017, China [58] | 60 (30/30) | T: 57.33 ± 1.59
C: 60.07 ± 1.61 | NA | Bushen huoxue fang | Diacerein, 50 mg/time, PO, QD | 4 | TER | | Wang Z, 2017, China [59] | 144 (72/72) | NA | NA | Bushen huoxue tongluo fang | Celecoxib, 100 mg/time, PO, QD | 12 | TER, VS, LYS | | Yuan JJ, 2017, China [60] | 70 (35/35) | T: 48.30 ± 5.60
C: 41.20 ± 4.80 | T: 18/17
C: 15/20 | Bushen huoxue tang | Celecoxib, 200 mg/time, PO, QD | 12 | VS, KS | | Pan JK, 2017, China [61] | 80 (40/40) | T: 64.53 ± 6.47
C: 64.55 ± 5.57 | T: 6/34
C: 5/35 | Longbie capsule | Celecoxib, 200 mg/time, PO, QD | 4 | TER, VS, LES, AE | | Xing QJ, 2018, China [62] | 137 (69/68) | T: 51.0 ± 8.0
C: 53.0 ± 9.0 | T: 31/38
C: 32/36 | Yiqi huayu bushen fang | Meloxicam, 7.5 mg/time, PO, QD | 6 | TER, VS, WS, AE |
|
|
